Multicenter Trial of Sentinel Node Biopsy for Breast Cancer Using Both Technetium Sulfur Colloid and Isosulfan Blue Dye
Top Cited Papers
- 1 January 2001
- journal article
- clinical trial
- Published by Wolters Kluwer Health in Annals of Surgery
- Vol. 233 (1) , 51-59
- https://doi.org/10.1097/00000658-200101000-00009
Abstract
To determine the factors associated with false-negative results on sentinel node biopsy and sentinel node localization (identification rate) in patients with breast cancer enrolled in a multicenter trial using a combination technique of isosulfan blue with technetium sulfur colloid (Tc99). Sentinel node biopsy is a diagnostic test used to detect breast cancer metastases. To test the reliability of this method, a complete lymph node dissection must be performed to determine the false-negative rate. Single-institution series have reported excellent results, although one multicenter trial reported a false-negative rate as high as 29% using radioisotope alone. A multicenter trial was initiated to test combined use of Tc99 and isosulfan blue. Investigators (both private-practice and academic surgeons) were recruited after attending a course on the technique of sentinel node biopsy. No investigator participated in a learning trial before entering patients. Tc99 and isosulfan blue were injected into the peritumoral region. Five hundred twenty-nine patients underwent 535 sentinel node biopsy procedures for an overall identification rate in finding a sentinel node of 87% and a false-negative rate of 13%. The identification rate increased and the false-negative rate decreased to 90% and 4.3%, respectively, after investigators had performed more than 30 cases. Univariate analysis of tumor showed the poorest success rate with older patients and inexperienced surgeons. Multivariate analysis identified both age and experience as independent predictors of failure. However, with older patients, inexperienced surgeons, and patients with five or more metastatic axillary nodes, the false-negative rate was consistently greater. This multicenter trial, from both private practice and academic institutions, is an excellent indicator of the general utility of sentinel node biopsy. It establishes the factors that play an important role (patient age, surgical experience, tumor location) and those that are irrelevant (prior surgery, tumor size, Tc99 timing). This widens the applicability of the technique and identifies factors that require further investigation.Keywords
This publication has 19 references indexed in Scilit:
- Intradermal Radiocolloid and Intraparenchymal Blue Dye Injection Optimize Sentinel Node Identification in Breast Cancer PatientsAnnals of Surgical Oncology, 1999
- Sentinel node biopsy in 70 unselected patients with breast cancer: increased feasibility by using 10 mCi radiocolloid in combination with a blue dye tracerEuropean Journal of Surgical Oncology, 1999
- The Sentinel Node in Breast Cancer — A Multicenter Validation StudyNew England Journal of Medicine, 1998
- Guidelines for Sentinel Node Biopsy and Lymphatic Mapping of Patients With Breast CancerAnnals of Surgery, 1998
- Intradermal blue dye to identify sentinel lymphnode in breast cancerThe Lancet, 1997
- Sentinel-node biopsy to avoid axillary dissection in breast cancer with clinically negative lymph-nodesThe Lancet, 1997
- Improved Axillary Staging of Breast Cancer with Sentinel LymphadenectomyAnnals of Surgery, 1995
- Lymphatic Mapping and Sentinel Lymphadenectomy for Breast CancerAnnals of Surgery, 1994
- Surgical resection and radiolocalization of the sentinel lymph node in breast cancer using a gamma probeSurgical Oncology, 1993
- Risk of Internal Mammary Lymph Node Metastases and Its Relevance on Prognosis of Breast Cancer PatientsAnnals of Surgery, 1983